A dual-peptide research formulation consisting of CJC-1295 (No DAC), a synthetic GHRH analog, and Ipamorelin, a selective GHSR-1a agonist, studied for their effects on growth hormone signaling and endocrine regulation in preclinical and clinical research. Premium Research Peptide.